Back to mobile site

B.Riley Reiterates Buy Rating on Journey Medical Corp. (DERM)

August 13, 2024 6:55 AM EDT Send to a Friend
B.Riley analyst Kalpit Patel reiterated a Buy rating and $8.00 price target on Journey Medical Corp. (NASDAQ: DERM).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login